TY  - JOUR
AU  - Kinross, Kathryn M.
AU  - Sheppard, Karen E.
AU  - Pearson, Richard B.
AU  - Phillips, Wayne A.
PY  - 2012
TI  - Targeting cancer with PI3K pathway inhibitors: who to aim at?
JF  - Translational Cancer Research; Vol 1, No 2 (August 01, 2012): Translational Cancer Research
Y2  - 2012
KW  - 
N2  - Breast and gynecological (ovarian, endometrial and cervical) cancers commonly harbor mutations activating the PI3K pathway, including PIK3CA mutation/amplification, PTEN loss or HER2 amplification. Insight from the successful development of many targeted cancer therapeutics suggests that these tumor types with a high prevalence of mutations in the PI3K pathway would be ideal candidates for therapy with inhibitors of that pathway. This was indeed the case with imatinib to target Bcr-Abl positive CML patients and cKIT mutant GIST tumors; vemurafenib to target B-RAFV600E melanoma; trastuzumab to target HER2 positive breast cancer; and crizotinib to target EML4-ALK positive lung tumors.
UR  - https://tcr.amegroups.org/article/view/382